Super exciting!! The FDA has just approved Argenx’s subcutaneous injection (given in the fatty tissue just under the skin) formulation of efgartigimod, called Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) to treat adults with generalized myasthenia gravis.
Efgartigimod alfa is the active agent in Vyvgart and a recombinant human hyaluronidase PH20 enzyme. That enzyme is crucial in the under-the-skin injection delivery, which takes only *90 SECONDS* to be administered. Into-the-vein or intravenous therapy takes about one hour.
Who is interested in this new treatment options? What are your thoughts?
- Jodi, Team Member